79352-78-6|去乙基阿莫地喹|N-Desethyl amodiaquine|MFCD08063555-范德生物科技公司

去乙基阿莫地喹

NMR下载 COA and HPLC MSDS下载
names：
N-Desethyl amodiaquine
CAS号：
79352-78-6
MDL Number： MFCD08063555
MF(分子式)： C18H18ClN3O MW(分子量)： 327.81
EINECS: Reaxys Number:
Pubchem ID:122068 Brand:BIOFOUNT

去乙基阿莫地喹(79352-78-6,N-Desethyl amodiaquine)属于一种有机化合物，称为4-氨基喹啉。这些是含有与喹啉环系统的4-位连接的氨基的有机化合物。去乙基阿莫地喹被认为是实际上不溶的（在水中）并且是相对中性的分子。在人的肝脏和肾脏组织中发现了去乙基阿莫地喹，在尿液和血液等多种生物流体中也发现了去乙基阿莫地喹。在细胞内，去乙基阿莫地喹主要位于细胞质和膜中。

货品编码	规格	纯度	价格 (¥)	现价(¥)	特价(¥)	库存描述	数量	总计 (¥)
YZM000809-10mg	10mg	99.9%	¥ 5568.00	¥ 5568.00		3-5天	- +	¥ 0.00
YZM000809-5mg	5mg	99.9%	¥ 2980.00	¥ 2980.00		3-5天	- +	¥ 0.00

大包装询价提供各种包装，敬请垂询
收藏商品商品点评加入购物车立即购买

快速询价

收起

你想询价的产品

*产品名称：

CAS号：

产品编号：

需求描述：

请准确填写您的联系方式，以便为您提供最好的服务。

*公司名称：

*电子邮箱：

联系人：

*电话：

*验证码：

询价

中文别名	去乙基阿莫地喹(79352-78-6,N-Desethyl amodiaquine);N-脱乙基阿莫地喹
英文别名	N-Desethyl amodiaquine(79352-78-6);desethylamodiaquine;Monodesethylamodiaquine
CAS号	79352-78-6
SMILES	OC1=CC=C(NC2=CC=NC3=CC(Cl)=CC=C23)C=C1CNCC
Inchi	InChI=1S/C18H18ClN3O/c1-2-20-11-12-9-14(4-6-18(12)23)22-16-7-8-21-17-10-13(19)3-5-15(16)17/h3-10,20,23H,2,11H2,1H3,(H,21,22)
InchiKey	VRXFDHAGFYWGHT-UHFFFAOYSA-N
分子式 Formula	C18H18ClN3O
分子量 Molecular Weight	327.81
闪点 FP	242.7±28.7 °C
熔点 Melting point	168-174°C
沸点 Boiling point	477.8±45.0 °C at 760 mmHg
Polarizability极化度	38.1±0.5 10-24cm3
密度 Density	1.3±0.1 g/cm3
蒸汽压 Vapor Pressure	0.0±1.2 mmHg at 25°C
溶解度Solubility	生物体外In Vitro:DMSO溶解度125 mg/mL(381.32 mM;Need ultrasonic)
性状	浅黄色至黄色固体粉末
储藏条件 Storage conditions	storage at -4℃ (1-2weeks), longer storage period at -20℃ (1-2years)

去乙基阿莫地喹(79352-78-6,N-Desethyl amodiaquine)实验注意事项：
1.实验前需戴好防护眼镜，穿戴防护服和口罩，佩戴手套，避免与皮肤接触。
2.实验过程中如遇到有毒或者刺激性物质及有害物质产生，必要时实验操作需要手套箱内完成以免对实验人员造成伤害
3.实验后产生的废弃物需分类存储，并交于专业生物废气物处理公司处理，以免造成环境污染

N-Desethyl amodiaquine(79352-78-6) Experimental considerations:
1. Wear protective glasses, protective clothing and masks, gloves, and avoid contact with the skin during the experiment.
2. The waste generated after the experiment needs to be stored separately, and handed over to a professional biological waste gas treatment company to avoid environmental pollution.

Tag:去乙基阿莫地喹(79352-78-6,N-Desethyl amodiaquine),去乙基阿莫地喹试剂,去乙基阿莫地喹抑制剂,去乙基阿莫地喹的作用,去乙基阿莫地喹的生产,去乙基阿莫地喹的厂家,去乙基阿莫地喹的价格,去乙基阿莫地喹的合成,去乙基阿莫地喹的纯度,去乙基阿莫地喹的外观,去乙基阿莫地喹的MSDS

产品说明	去乙基阿莫地喹(79352-78-6,N-Desethyl amodiaquine)是 Amodiaquine 的主要生物活性代谢产物,去乙基阿莫地喹是一种抗寄生虫剂
Introduction	N-Desethyl amodiaquine(79352-78-6,去乙基阿莫地喹) is the main bioactive metabolite of Amodiaquine, and desethyl amodiaquine is an antiparasitic agent
Application1
Application2
Application3

警示图
危险性	warning
危险性警示	Not available
安全声明	H303吞入可能有害+H313皮肤接触可能有害+H2413吸入可能对身体有害
安全防护	P264处理后彻底清洗+P280戴防护手套/穿防护服/戴防护眼罩/戴防护面具+P305如果进入眼睛+P351用水小心冲洗几分钟+P338取出隐形眼镜（如果有）并且易于操作,继续冲洗+P337如果眼睛刺激持续+P2393获得医疗建议/护理
备注	实验过程中防止吸入、食入，做好安全防护

象形图
信号警告	Warning
GHS危险说明	Aggregated GHS information provided by 40 companies from 2 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies. H315 (100%): Causes skin irritation [Warning Skin corrosion/irritation] H319 (100%): Causes serious eye irritation [Warning Serious eye damage/eye irritation] H335 (100%): May cause respiratory irritation [Warning Specific target organ toxicity, single exposure; Respiratory tract irritation] Information may vary between notifications depending on impurities, additives, and other factors. The percentage value in parenthesis indicates the notified classification ratio from companies that provide hazard codes. Only hazard codes with percentage values above 10% are shown.
防范说明代码	P261, P264, P271, P280, P302+P352, P304+P340, P305+P351+P338, P312, P321, P332+P313, P337+P313, P362, P403+P233, P405, and P501 (The corresponding statement to each P-code can be found at the GHS Classification page.)

Apoptosis contributes to the cytotoxicity induced by amodiaquine and its major metabolite N-desethylamodiaquine in hepatic cells PMID 31629065;

Influence of MAMA decoction, an Herbal Antimalarial, on the Pharmacokinetics of Amodiaquine in Mice PMID 31642009; European journal of drug metabolism and pharmacokinetics 2020 Feb; 45(1):81-88

Adherence and Population Pharmacokinetic Properties of Amodiaquine When Used for Seasonal Malaria Chemoprevention in African Children PMID 31652336

Influence of LAR and VAR on Para-Aminopyridine Antimalarials Targetting Haematin in Chloroquine-Resistance PMID 27483471; PloS one 2016; 11(8):e0160091

Confirmation of Plasmodium falciparum in vitro resistance to monodesethylamodiaquine and chloroquine in Dakar, Senegal, in 2015 PMID 28302108; Malaria journal 2017 03; 16(1):118

In vivo and in vitro efficacy of amodiaquine against Plasmodium falciparum in an area of continued use of 4-aminoquinolines in East Africa
Abstract:In light of reports of increasing resistance of parasites to amodiaquine in African countries in which Plasmodium falciparum is endemic as well as the paucity of recent in vitro sensitivity data, we assessed the in vivo and in vitro sensitivity to amodiaquine of P. falciparum isolates from 128 pediatric outpatients (0.5-10 years old) in Pingilikani, Kilifi District, Kenya, who were treated with amodiaquine (10 mg/kg/day for 3 days). The polymerase chain reaction-corrected parasitological cure rate on day 28 (by Kaplan-Meier analysis) was 82% (95% confidence interval [CI], 74%-88%). Twenty-six percent (17/66) of tested pretreatment P. falciparum field isolates had 50% in vitro growth inhibition at concentrations of N-desethyl-amodiaquine (DEAQ)-the major biologically active metabolite of amodiaquine-above the proposed resistance threshold of 60 nmol/L, but baseline median DEAQ 50% inhibitory concentration values were not associated with subsequent risk of asexual parasite recrudescence (29 nmol/L [95% CI, 23-170 nmol/L] and 34 nmol/L [95% CI, 30-46 nmol/L] for patients with and those without recrudescences, respectively). The median absolute neutrophil count dropped by 1.3 X 10(3) cells/microL (95% CI, -1.7 X 10(3) to -0.7 X 10(3) cells/microL) between days 0 and 28. The high prevalence of in vitro and in vivo resistance precludes the use of amodiaquine on its own as second-line treatment. These findings also suggest that the value of amodiaquine combinations as first- or second-line treatment in areas with similar patterns of 4-aminoquinoline resistance should be reassessed.

对不起，暂无产品评价！

MSDS

SDS 1.0 中文

展开

SDS 1.0 英文

展开